Miltenyi, ATLATL build cell, gene therapy centre in Shanghai

To accelerate the development of cell and gene therapy, ATLATL centre and Miltenyi Biotec have cooperated to build ATLATL-MACS centre for Gene and Cell Therapy.

Miltenyi is in the design, development, manufacturing, and integration of products and provides innovative portfolio of cellular technologies used seamlessly in a variety of research, translational, and clinical applications.

ATLATL has laboratory space, designed as a launchpad for high-potential life sciences. The centre is approximately 25,000 square feet, functions as a talent training centre, expedites process development, and cell and gene therapy platforms and includes specialized laboratories for cell collection, separation, production, microscopic imaging, and storage and transportation.

In recent years, advances in gene editing technology and viral vectors, gene and cell therapy has developed from theory to reality with major breakthroughs, as a promising emerging sector in medicine.

ATLATL and Miltenyi spent nearly one year on planning and construction, finally built the ATLATL-MACS centre in March 2019 with a specialized focus to remove hurdles encountered in current treatments. The centre offers a complete research and development platform and will actively train researchers, work with more R&D teams to conduct new process development and application discovery, establish complete standardized operating procedures, assist pharmaceutical companies conduct accurate disease diagnosis and efficacy evaluations, accelerating clinical transformation and commercialization of gene and cell therapy.

The ATLATL-MACS centre covers the biomedical industry chain and will gather a series of innovative teams, which have important strategic significance for the development of local life sciences. The centre will provide services to biological companies through more than 10 million euro cutting-edge instruments and expert team.

Miltenyi Biotec has previously collaborated with many giant pharmaceuticals, such as GlaxoSmithKline on the "industrialization" of cell and gene therapy. Differently, the cooperation between Miltenyi and ATLATL is an open platform to biotech companies. The centre will help biopharmaceutical companies and scientific research institutions integrate R&D, training, commercialization.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.